The American College of Chest Physicians (CHEST) recently released a new clinical guideline on biologic management in severe ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Smoking, higher body mass index (BMI), and previous exposure to biologics were linked to poorer responses to biologics among patients with psoriasis, in a meta-analysis. Older age (odds ratio [OR], ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...

Biologic treatments for eczema are medications usually prescribed for people with moderate to severe disease. These medications are administered by injection and are typically only prescribed when ...

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment. This content was ...

Biologic therapy in HS shows dual benefits: improved skin lesions and potential systemic anti-inflammatory effects, as indicated by lipid profile changes. Early treatment initiation is crucial for ...

A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...